Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy benefits

11 April 2014

The effect of a therapy on overall survival and progression-free survival are attributes that most influence surveyed US and European hematological oncologists' prescribing decisions for relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

In addition, according to a new report from Decision Resources, US and European hematological oncologists, as well as US payers indicate that improving overall survival is one of the greatest unmet needs in R/R CLL/SLL.

The novel mechanism of action of first-in-class kinase inhibitors ibrutinib (Johnson & Johnson (NYSE: JNJ)/Janssen/Pharmacyclics' Imbruvica [ibrutinib] and idelalisib (Gilead Sciences; Nasdaq: GILD) has elicited great enthusiasm from interviewed experts. These experts perceive that ibrutinib and idelalisib offer a major advantage in efficacy compared with the current major-market sales and patient share leader, FCR*.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK